Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Human Organoids Market size is projected to increase from USD 2.83 billion to USD 24.88 billion, exhibiting a CAGR of over 18.2% during the forecast period, from 2025 through 2037. In the year 2025, the industry size of human organoids is estimated at USD 3.24 billion.
The market growth can be attributed to the rising incidence of infectious diseases worldwide. According to the Texas Biomedical Research Institute, infectious diseases kill more than 17 million people every year, and 30 new diseases have emerged in the last 20 years. Organoids are proven to be transformative novel tools for the study of human infectious diseases. For instance, lung organoids have been utilized to study respiratory viral infections such as SARS-CoV-2. Researchers are extensively using organoids to study mechanisms of diseases acting within human tissues.
Additionally, the rising demand for biobanking and tumor modeling is expected to propel market growth during the assessed time. According to the Orfonline Research Observation report, there were 340 operational biobanks present globally in 2023. Tumor organoid biobanks are considered to be a new platform for medical research. Also, the biobank of organoids allows scientists to gain access to standardized protocols for the fabrication of human organoids. Human organoids may also be deployed for the customization of therapy or personalized medicine.
Human Organoids Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing number of organ transplantation procedures: The number of donors is much less than the number of people who need organ transplantation. According to data published by Penn Medicine in 2023, more than 100,000 people are waiting for transplantation in the U.S. Organoids are considered an alternative cell source for tissue engineering and aim to overcome the shortage of donors. These organoids are also helpful in drug testing of transplantation therapy.
- Rising number of experiments in genetic science: Organoids are used as a tool to study gene function and cell development. The technology is used in investigating gene roles and studying cell development and functions. According to the World Economic Forum in April 2024, a USD 3.1 billion research program in the U.S. has already identified more than 275 million genetic variants that could help in creating health equity. Moreover, preclinical drug testing of regenerative medicines uses human organoids in biomedical research.
Challenges
- Inadequate infrastructure for 3D cell culture: The availability of the necessary equipment to use advanced techniques is one of the prerequisites for conducting 3D cell culture-based research. Moreover, deploying the equipment and infrastructure of 3D cell culture demands huge capital and time.
- Difficulty in incorporating human organoids in workflows: The utility of the organoids is tempered by a variety of limitations such as limited maturation, and lack of high-fidelity cell types. Also, lack of standardization and variability in tissue sampling methods introduce challenges in organoid cultures.
Human Organoids Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
18.2% |
|
Base Year Market Size (2024) |
USD 2.83 billion |
|
Forecast Year Market Size (2037) |
USD 24.88 billion |
|
Regional Scope |
|
Human Organoids Market Segmentation
Product (Pancreas, Kidney, Lungs, Heart, Liver Models)
The kidney segment is estimated to gain the largest human organoids market share over the projected time frame attributed to the increasing number of kidney transplants performed globally as compared to other procedures. According to the American Kidney Fund, currently, there are more than 92,000 people on the national transplant list waiting for a kidney. Moreover, there has been a significant growth in kidney-related diseases which is projected to contribute to the segment growth. National Kidney Foundation states that currently 10% of the population globally is affected by chronic kidney disease. Organoid transplantation promotes the formation of target mesangial and pericyte cells in kidney organoids.
End-user (Biotech & Pharma, Academic & Research Institutes, Hospitals & Diagnostic Centers)
The biotech & pharma industry segment in human organoids market is expected to garner a significant share on the back of rising focus on developing new drugs. In 2022, the Center for Drug Evaluation and Research approved 37 novel drugs as new therapeutic biological products. Organoids are replicated from the patient's tissue that simulate the response to radiation therapy and have the potential to act as biomarkers. Organoids have garnered remarkable attention in drug discovery due to their potential to revolutionize the drug development process.
Our in-depth analysis of the global human organoids market includes the following segments:
|
Product |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportHuman Organoids Industry - Regional Synopsis
Asia Pacific Market Statistics
The Asia Pacific human organoids market is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the rising need for organ transplantation and donation. According to the National Institutes of Health in 2022, 453.3 million people were suffering from chronic kidney disorders across southern, eastern and southern eastern regions of Asia. Furthermore, rising cases of infectious disease in the region are expected to boost the market growth.
In India, the market is expected to register rapid growth during the forecast period owing to rising incidence of cancer, government initiatives to promote human organoids, and supportive regulations for the development and commercialization of advanced human organoid products. Moreover, rising investments in gene mutation and cancer research and rapid adoption of advanced technologies are expected to fuel market growth in India going ahead.
North America Market Forecast
The human organoids market in North America is projected to offer lucrative growth opportunities due to rising investment in research and development activities and the presence of robust healthcare and research facilities. The National Science Foundation stated that in the U.S., investment in R&D reached USD 886 billion in 2022. Also, there is commercialization of organoid models and stem cell research. In Canada, researchers are using cerebral organoids to treat neurological diseases. In March 2024, Sinai Health infused USD 10 million in funding to fuel the creation of lab-grown organoids for drug discovery.
Companies Dominating the Human Organoids Landscape
- BioVT LLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Thermo Fisher Scientific Inc.
- Corning Incorporated
- Emulate Bio
- Organovo Holdings Inc.
- Zen-Bio Inc
- Hurel Corporation
- Cellink AB
- Biopredic International
The competitive landscape of the human organoids market is rapidly evolving as established key players, healthcare giants and new entrants are investing in drug development. Key players in the market are focused on developing new technologies and products catering to the stringent regulatory norms and consumer demand. These key players are adopting several strategies such as mergers and acquisitions, joint ventures, partnerships, and novel product launches to enhance their product base and strengthen their market position. Here are some key players operating in the global human organoids market:
In the News
- In January 2025, MilliporeSigma joined hands with Opentrons Labworks, Inc. to fabricate and verify the platform utilizing the broad offering of automation-enabled assays. Customers will be able to place orders for workstations from mid-2025.
- In June 2024, Atelerix Ltd. and DefiniGEN Ltd announced the successful shipment of in vitro liver models to top-tier pharma customers in the U.S. These laboratories created liver models that mimic the natural behavior of the liver in the human body.
Author Credits: Radhika Pawar
- Report ID: 3240
- Published Date: Feb 20, 2025
- Report Format: PDF, PPT
